BioCer Announces Attendance at EACTS and Continued Expansion of Asia-Pacific Market - China Approves HaemoCer™

BAYREUTH, Germany, October 8, 2014 /PRNewswire/ --

BioCer Entwicklungs GmbH (BCE), a German implantable biological medical device development and manufacturing company, announced today that it has achieved approval to commence sales of HaemoCer™, an Absorbable Polysaccharide Hemostat (APH), in the People's Republic of China (PRC). HaemoCer™ is a plant-based powdered hemostat for the control of blood loss in surgery. BCE's expansion in the Asia-Pacific markets is managed by APEC-based Mr. Philip MacPherson, VP International Sales.

"BioCer has now achieved near comprehensive Asia-Pacific regional representation, and the addition of the PRC approval of HaemoCer™ is a significant milestone," Dr Markus Heinlein, Managing Director stated. "The entry into China of our first product HaemoCer™ has been assisted by the early establishment of regional sales representation in the Asia-Pacific region. BCE are pleased Chinese surgeons and patients will now share the benefits of our technology. Our new Health Canada approval is also further evidence of strong international acceptance of our technology."

The PRC approval of HaemoCer™ expands an international sales network encompassing Australia, Hong Kong, India, Korea, Malaysia, New Zealand, Singapore and Thailand within the APEC region. BCE will be exhibiting at the EACTS, Milan, Italy, 11-15^th October and the CMEF, Chongqing, China, 23-26^th October 2014. BioCer welcomes expressions of interest in distribution or licensing queries, please visit http://www.biocer-gmbh.de or email [email protected].

About HaemoCer™ 

HaemoCer™ Absorbable Polysaccharide Hemostat (APH) has been developed to meet the challenges of bleeding in surgery. Biocer's Polysaccharide Ultra-hydrophilic Resorbable Engineering (PURE) process modifies plant-based polymers to create a highly absorptive, biocompatible agent which enhances and accelerates the natural clotting cascade. The PURE technology format of HaemoCer™ APH contains no human or animal components, and is resorbed within days.

SOURCE BioCer Entwicklungs-GmbH

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED